TLR3 and hepatocellular carcinoma: A phase I clinical trial by the combination of intra-tumoral injection of the TLR3 agonist poly-ICLC after local radiation at relatively low dose (2.5 Gy/fraction, a total dose of 22.5 Gy) and local regional treatment (TAE or TACE) to treat advanced HCC patients, has proved to be safe and tolerable (de la Torre et al, 2017).